(Q44675016)

5 December 2017

title

Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy (English)

1 reference

5 December 2017

1 reference

Tianen Yang

1

1 reference

5 December 2017

Gary M Brittenham

2

1 reference

5 December 2017

Wei-Qiang Dong

3

1 reference

5 December 2017

Matthew N Levy

4

1 reference

5 December 2017

Carlos A Obejero-Paz

5

1 reference

5 December 2017

Yuri A Kuryshev

6

1 reference

5 December 2017

Arthur M Brown

7

1 reference

5 December 2017

publication date

1 November 2003

1 reference

5 December 2017

published in

Translational Research

1 reference

5 December 2017

volume

142

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

332-340

1 reference

Heart failure in beta-thalassemia

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Survival and disease complications in thalassemia major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Cardiac involvement in thalassemia intermedia: a multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Haemochromatosis presenting as congestive cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Cardiac dysfunction because of secondary hemochromatosis caused by congenital non-spherocytic hemolytic anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Sick sinus syndrome as the early manifestation of cardiac hemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Refractory biventricular heart failure in secondary hemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

LATE CARDIAC COMPLICATIONS OF CHRONIC, SEVERE, REFRACTORY ANEMIA WITH HEMOCHROMATOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Reversal of haemochromatotic cardiomyopathy in beta thalassaemia by chelation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Sustained normalization of cardiac function by chelation therapy in thalassaemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Reversible cardiac dysfunction in hemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Hepatic stellate cells are not subjected to oxidant stress during iron-induced fibrogenesis in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Bimodal cardiac dysfunction in an animal model of iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Longitudinal assessment of cardiac status by echocardiographic evaluation of left ventricular diastolic function in thalassaemic children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Right ventricular diastolic function in β-thalassemia major: Echocardiographic and clinical correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Preclinical cardiac dysfunction in transfusion-dependent children and young adults detected with low-dose dobutamine stress echocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Assessment of the developmental toxicity of deferoxamine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

The toxic effects of desferrioxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Deferoxamine pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Practical management of iron overload.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

The absorption, distribution and utilization of intramuscularly administered iron-dextran: a radio-isotope study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Availability of iron dextran for hemoglobin synthesis as studied with phlebotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Iron regulation of hepatic macrophage TNFalpha expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

Role of deferiprone in chelation therapy for transfusional iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

7 January 2021

Secondary iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900135-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-2143(03)00135-5

1 reference

5 December 2017

1 reference